Recent 8-K filings for SKVI

• January 23, 2025, 6:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  Skinvisible licensee Quoin reports positive Netherton Syndrome clinical results; $5M milestone payment upon approval

  Quoin's QRX003 (using Invisicare) showed 'severe' to 'mild' improvement after 6 weeks in Netherton Syndrome studies.

• October 3, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Skinvisible announces 99.6% transdermal penetration of GLP-1 drug in preclinical study

  GLP-1 drug danuglipron formulated with Invisicare showed 99.6% penetration over 6 hours in Franz cell diffusion studies.

• June 4, 2024, 7:59 PM ET other material materiality 0.30 neutral item 3.02

  Skinvisible issues 350,000 units at $0.10/unit in private placement

  Each unit consists of one common share and a warrant to purchase 0.5 share at $0.20 per share.

• May 29, 2024, 7:59 PM ET other material materiality 0.30 positive item 7.01item 9.01

  Skinvisible files provisional patent for transdermal obesity drug delivery using Invisicare

  Provisional patent filed for transdermal composition of CB-1 receptor antagonists and/or GLP-1 receptor agonists.

• October 25, 2023, 7:59 PM ET other material materiality 0.40 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Skinvisible replaces auditor Gries & Associates with GreenGrowth CPAs after Gries' sale

  On Oct 17, 2023, engaged GreenGrowth CPAs as new independent accountant; effective Oct 24, 2023 after Gries sold its business.

• January 13, 2022, 6:59 PM ET other material materiality 0.70 negative item 4.01item 9.01

  Skinvisible changes auditor; Prager Metis declines reappointment over internal control issues

  Prager Metis CPAs declined reappointment as auditor on Jan 7, 2022; Gries and Associates engaged Jan 12, 2022.

Materiality & sentiment trend

Max materiality 0.70 · Median 0.48 · Most common event other_material

3 positive 1 negative 2 neutral

source · SKVI on sec.gov